Provided by Tiger Trade Technology Pte. Ltd.

Quince Therapeutics, Inc.

1.34
+0.11008.94%
Pre-market: 1.360.0185+1.38%07:02 EDT
Volume:2.91M
Turnover:3.83M
Market Cap:21.84M
PE:-0.08
High:1.40
Open:1.18
Low:1.17
Close:1.23
52wk High:45.50
52wk Low:0.8000
Shares:16.30M
Float Shares:15.70M
Volume Ratio:0.38
T/O Rate:18.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.8000
EPS(LYR):-13.1357
ROE:-247.78%
ROA:-30.31%
PB:-0.61
PE(LYR):-0.10

Loading ...

Company Profile

Company Name:
Quince Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
36
Office Location:
611 Gateway Boulevard,Suite 273,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Directors

Name
Position
Dirk Thye
Chief Executive Officer, Chief Medical Officer and Director
David Lamond
Director and Chairperson of the Board
Christopher J. Senner
Director

Shareholders

Name
Position
Dirk Thye
Chief Executive Officer, Chief Medical Officer and Director
Brendan Hannah
Chief Operating Officer, Chief Business Officer and Chief Compliance Officer
Charles Ryan
President